{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:06:47Z","timestamp":1794391607733,"version":"4.9.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.11.088","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T07:58:50Z","timestamp":1579161530000},"page":"1860-1868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice"],"prefix":"10.1016","volume":"38","author":[{"given":"Barnali","family":"Nath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Vandna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari Mohan","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minakshi","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-6013","authenticated-orcid":false,"given":"Sachin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.11.088_b0005","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/nm1144","article-title":"Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses","volume":"10","author":"Mackenzie","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.11.088_b0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.11.088_b0015","unstructured":"Halstead SB. Arboviruses of the pacific and Southeast Asia; 1992."},{"key":"10.1016\/j.vaccine.2019.11.088_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40794-017-0057-x","article-title":"The changing epidemiology of Japanese encephalitis and New data: the implications for New recommendations for Japanese encephalitis vaccine","volume":"3","author":"Connor","year":"2017","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"10.1016\/j.vaccine.2019.11.088_b0025","doi-asserted-by":"crossref","unstructured":"Beckham D, Kenneth LT. Encephalitis, 8th ed.; 2015. p. 1144\u201363.","DOI":"10.1016\/B978-1-4557-4801-3.00091-6"},{"key":"10.1016\/j.vaccine.2019.11.088_b0030","unstructured":"MacLachlan NJa, Dubovi EJ. Flaviviridae. Fenner's veterinary virology, 5th ed.; 2016. p. 602."},{"key":"10.1016\/j.vaccine.2019.11.088_b0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s13071-017-2354-7","article-title":"Meta-analyses of the proportion of Japanese encephalitis virus infection in vectors and vertebrate hosts","volume":"10","author":"Oliveira","year":"2017","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2019.11.088_b0040","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/jtm\/tay009","article-title":"Japanese encephalitis: the vectors, ecology and potential for expansion","volume":"25","author":"Pearce","year":"2018","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2019.11.088_b0045","series-title":"Flaviviruses","author":"Monath","year":"1996"},{"key":"10.1016\/j.vaccine.2019.11.088_b0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/erv.11.180","article-title":"Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex","volume":"11","author":"Lobigs","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.11.088_b0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1309\/LM5YWS85NJPCWESW","article-title":"Overview of the flaviviridae with an emphasis on the Japanese encephalitis group viruses","volume":"40","author":"Schweitzer","year":"2009","journal-title":"Lab Med"},{"key":"10.1016\/j.vaccine.2019.11.088_b0060","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/JVI.77.5.3091-3098.2003","article-title":"Origin and evolution of Japanese encephalitis virus in southeast Asia","volume":"77","author":"Solomon","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0065","series-title":"Flaviviridae: the viruses and their replication","author":"Lindenbach","year":"2007"},{"key":"10.1016\/j.vaccine.2019.11.088_b0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.micinf.2011.01.002","article-title":"Japanese encephalitis virus: from genome to infectome","volume":"13","author":"Unni","year":"2011","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2019.11.088_b0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus genome organization, expression, and replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0042-6822(87)90144-9","article-title":"Complete nucleotide sequence of the Japanese encephalitis virus genome RNA","volume":"161","author":"Sumiyoshi","year":"1987","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.11.088_b0085","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.1128\/JVI.73.12.10137-10145.1999","article-title":"Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines","volume":"73","author":"Chen","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0090","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1128\/JVI.06072-11","article-title":"Crystal structure of the Japanese encephalitis virus envelope protein","volume":"86","author":"Luca","year":"2012","journal-title":"J Virol"},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2019.11.088_b0095","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1099\/0022-1317-78-11-2711","article-title":"The molecular basis of virulence of the encephalitogenic flaviviruses","volume":"78","author":"McMinn","year":"1997","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0100","series-title":"Flaviviruses","author":"Monath","year":"1990"},{"key":"10.1016\/j.vaccine.2019.11.088_b0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12985-016-0590-7","article-title":"Flavivirus NS1: a multifaceted enigmatic viral protein","volume":"13","author":"Rastogi","year":"2016","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2019.11.088_b0110","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/hv.26902","article-title":"Japanese encephalitis: the virus and vaccines","volume":"10","author":"Yun","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.11.088_b0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/14712598.8.1.95","article-title":"Current use and development of vaccines for Japanese encephalitis","volume":"8","author":"Beasley","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.11.088_b0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.11.088_b0125","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/QCO.0b013e32833c1d01","article-title":"Japanese encephalitis: update on vaccines and vaccine recommendations","volume":"23","author":"Wilder-Smith","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.088_b0130","first-page":"1","article-title":"Centers for Disease C, Prevention. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Fischer","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2019.11.088_b0135","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1016\/j.vaccine.2009.09.006","article-title":"Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB\/c mice","volume":"27","author":"Verma","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0168-1702(96)01323-8","article-title":"A 27 amino acid coding region of JE virus E protein expressed in E. coli as fusion protein with glutathione-S-transferase elicit neutralizing antibody in mice","volume":"43","author":"Seif","year":"1996","journal-title":"Virus Res"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2019.11.088_b0145","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1099\/0022-1317-70-8-2037","article-title":"Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein","volume":"70","author":"Mason","year":"1989","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0150","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/0264-410X(95)00097-K","article-title":"Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system","volume":"13","author":"Seif","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13550280390218454","article-title":"Development of a recombinant vaccine against Japanese encephalitis","volume":"9","author":"Kaur","year":"2003","journal-title":"J Neurovirol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0042-6822(91)90788-D","article-title":"Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus","volume":"185","author":"Konishi","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.11.088_b0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4269\/ajtmh.1993.48.412","article-title":"Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein","volume":"48","author":"Jan","year":"1993","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.11.088_b0170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0042-6822(91)90034-9","article-title":"Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection","volume":"180","author":"Mason","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.11.088_b0175","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2019.11.088_b0180","first-page":"46","article-title":"Newcastle disease virus as a vaccine vector for humans","volume":"10","author":"Bukreyev","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.vaccine.2019.11.088_b0185","doi-asserted-by":"crossref","unstructured":"Kaleta EF, Baldauf C. Newcastle disease in free-living and pet birds. In: Alexander DJ, editor. Newcastle disease developments in veterinary virology. MA Springer: Boston; 1988.","DOI":"10.1007\/978-1-4613-1759-3_12"},{"key":"10.1016\/j.vaccine.2019.11.088_b0190","series-title":"The biology of paramyxoviruses","article-title":"Newcastle disease and related avian paramyxoviruses","author":"Samal","year":"2011"},{"key":"10.1016\/j.vaccine.2019.11.088_b0195","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ps\/82.6.899","article-title":"Recombinant Newcastle disease virus as a vaccine vector","volume":"82","author":"Huang","year":"2003","journal-title":"Poult Sci"},{"key":"10.1016\/j.vaccine.2019.11.088_b0200","doi-asserted-by":"crossref","unstructured":"Kim SH, Samal SK. Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. Viruses 2016;8.","DOI":"10.3390\/v8070183"},{"key":"10.1016\/j.vaccine.2019.11.088_b0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.procbio.2017.12.001","article-title":"Production of recombinant Erns protein of classical swine fever virus and assessment of its enzymatic activity: a recombinant Newcastle disease virus-based approach","volume":"66","author":"Kumar","year":"2018","journal-title":"Process Biochem"},{"key":"10.1016\/j.vaccine.2019.11.088_b0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00705-019-04425-4","article-title":"Evaluation of surface glycoproteins of classical swine fever virus as immunogens and reagents for serological diagnosis of infections in pigs: a recombinant Newcastle disease virus approach","volume":"164","author":"Kumar","year":"2019","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0215","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1073\/pnas.54.3.794","article-title":"Isolation of the nucleic acid of Newcastle disease virus (NDV)","volume":"54","author":"Duesberg","year":"1965","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.11.088_b0220","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1128\/JVI.00367-11","article-title":"Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens","volume":"85","author":"Kumar","year":"2011","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.11.088_b0225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/03079457409353840","article-title":"Newcastle disease virus pathotypes","volume":"3","author":"Alexander","year":"1974","journal-title":"Avian Pathol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/03079457708418208","article-title":"Procedures for the haemagglutination and the haemagglutination inhibition tests for avian infectious bronchitis virus","volume":"6","author":"Alexander","year":"1977","journal-title":"Avian Pathol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0240","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.vetimm.2016.03.004","article-title":"Development of single dilution immunoassay to detect E2 protein specific classical swine fever virus antibody","volume":"172","author":"Kumar","year":"2016","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0245","series-title":"Animal influenza virus","first-page":"313","article-title":"Serum virus neutralization assay for detection and quantitation of serum-neutralizing antibodies to influenza a virus in swine","author":"Gauger","year":"2014"},{"key":"10.1016\/j.vaccine.2019.11.088_b0250","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.vaccine.2013.11.016","article-title":"Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain","volume":"32","author":"Calvert","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0255","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1016\/j.vaccine.2010.02.105","article-title":"Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities","volume":"28","author":"Yu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0260","first-page":"105","article-title":"Japanese encephalitis vaccines: current vaccines and future prospects","volume":"267","author":"Monath","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.micpath.2017.08.046","article-title":"Enhanced cytopathic effect of Japanese encephalitis virus strain SA14-14-2: probable association of mutation in amino acid of its envelope protein","volume":"111","author":"Nath","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2019.11.088_b0270","doi-asserted-by":"crossref","unstructured":"WHO. Global advisory committee on vaccine safety, 9\u201310 June 2005. Wkly Epidemiol Rec 2005;80:242\u20137.","DOI":"10.1109\/EPIA.2005.341247"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.11.088_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0264-410X(00)00037-2","article-title":"New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO\/CVI meeting, Bangkok, Thailand, 13\u201315 October 1998","volume":"18","author":"Tsai","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0280","unstructured":"WHO. Recommendations to assure the quality, safety and efficacy of Japanese encephalitis vaccine (live, attenuated) for human use. 58th meeting of the WHO expert committee on biological standardization. Geneva; 2007."},{"key":"10.1016\/j.vaccine.2019.11.088_b0285","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/21645515.2017.1414763","article-title":"Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children","volume":"14","author":"Chanthavanich","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.11.088_b0290","doi-asserted-by":"crossref","unstructured":"Ferguson M, Kurane I, Wimalaratne O, Shin J, Wood D, group WHOic. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1\u20132 June 2006. Vaccine 2007;25:5233\u201343.","DOI":"10.1016\/j.vaccine.2007.05.034"},{"key":"10.1016\/j.vaccine.2019.11.088_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078521","article-title":"Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector","volume":"8","author":"Khattar","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.11.088_b0300","doi-asserted-by":"crossref","first-page":"12088","DOI":"10.1128\/JVI.75.24.12088-12097.2001","article-title":"Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites","volume":"75","author":"Fournillier","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/jvi.66.1.172-182.1992","article-title":"Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons","volume":"66","author":"Haigwood","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0310","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1128\/JVI.76.15.7642-7650.2002","article-title":"Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression","volume":"76","author":"Wertz","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0315","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0014-5793(99)00960-6","article-title":"Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication","volume":"456","author":"Sakai","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2019.11.088_b0320","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.141.10.3606","article-title":"Protection of mice against Japanese encephalitis virus by passive administration of monoclonal antibodies","volume":"141","author":"Kimura-Kiroda","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0325","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/0042-6822(92)90526-U","article-title":"Mice immunized with a subviral particle containing the Japanese encephalitis virus prM\/M and E proteins are protected from lethal JEV infection","volume":"188","author":"Konishi","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.11.088_b0330","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0264-410X(99)00180-2","article-title":"Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies","volume":"18","author":"Ashok","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0335","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1128\/JVI.74.9.4244-4252.2000","article-title":"A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice","volume":"74","author":"Chang","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.11.088_b0340","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0264-410X(94)00059-V","article-title":"Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection","volume":"13","author":"Srivastava","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0345","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.vaccine.2011.07.058","article-title":"Enhancing the utility of a prM\/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene","volume":"29","author":"Ishikawa","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.088_b0350","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/JVI.72.1.191-200.1998","article-title":"DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice","volume":"72","author":"Lin","year":"1998","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:39:49Z","timestamp":1759401589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316482"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}